Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 1999 June;41(2) > Panminerva Medica 1999 June;41(2):89-92





A Journal on Internal Medicine

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6




Panminerva Medica 1999 June;41(2):89-92

language: English

Utility and com­pli­ca­tions of per­ma­nent ­venous ­access devic­es (­PVAD) in onco­log­i­cal treat­ments. Follow-up of 100 cas­es

Groebli Y., Wutrich P., Safa M., Tshantz P., Callewaert G.*, Piguet D.

From the Service de Chirurgie * Service d’Oncologie Hôpital des Cadolles, Neuchâtel, Switzerland


Background. Permanent ­venous ­access devic­es (­PVAD) are now­a­days rou­tine­ly implant­ed and ­used ­with ­some mor­bid­ity for the onco­log­i­cal treat­ments. The ade­quate tim­ing of implan­ta­tion ­based on the num­ber of treat­ments, the sur­vi­val ­rate and the com­pli­ca­tions has not ­yet been ­well esti­mat­ed.
Methods. A hun­dred per­ma­nent ­venous ­access devic­es ­placed in onco­log­i­cal ­patients ­were fol­lowed-up pros­pec­tive­ly.
Results. No mor­tal­ity was ­seen due to the sur­gi­cal act. A 11% mor­bid­ity ­rate was not­ed, large­ly due to infec­tions, ­with 6 ­patients need­ing a sec­ond sur­gery. On aver­age, 6 chem­o­ther­a­py ­cycles ­were ­done ­after plac­ing of the per­ma­nent ­venous ­access ­device.
Conclusions. Due to ­these ­results and an aver­age sur­vi­val ­rate of 10.7 ­months, we sug­gest the plac­ing of a per­ma­nent ­venous ­access ­device ear­ly in the man­age­ment of onco­log­i­cal ­patients requir­ing chem­o­ther­a­py ­cycles, so as to ­increase the com­fort of the ­patient and to safe­guard his periph­er­al ­venous ­system.

top of page

Publication History

Cite this article as

Corresponding author e-mail